Summit Therapeutics (SUMM)
SUMM Share PerformanceMore
|52 week high||262.00 04/10/16|
|52 week low||88.00 07/04/16|
|52 week change||106.50 (110.94%)|
|4 week volume||1,118,250 28/02/17|
Media for (SUMM)
Presenter: Mark Wilcox
Presenter: Mark Wilcox
- 1 of 2
Latest News« previous» nextMore
15/03/2017 - 12:00 RNS
Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 27 TH ANNUAL HEALTHCARE CONFERENCE Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SU...
05/03/2017 - 23:50 Trends and Targets
FTSE FOR THE WEEK (FTSE:UKX) Friday was irritating. It's one thing to speculate "all the action will happen at the open...
28/02/2017 - 13:00 RNS
Summit Therapeutics Recognises Tenth Annual Rare Disease Day Summit Therapeutics plc ('Summit' or 'the Company') SUMMIT THERAPEUTICS RECOGNISES 10 TH ANNUAL RARE DISEASE DAY Oxford, UK, 28 February 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies f...
23/02/2017 - 13:15 RNS
Summit Therapeutics plc: Exercise of Warrants Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...
02/02/2017 - 15:10 StockMarketWire
Summit Therapeutics has announced that company management will participate in three upcoming investor conferences ...
02/02/2017 - 13:00 RNS
Summit Therapeutics to Participate in February Investor Conferences Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES Oxford, UK, 2 February 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...
01/02/2017 - 14:36 StockMarketWire
Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory ...
01/02/2017 - 13:00 RNS
Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 - Summit Therapeutics plc (AIM...
|Dividend yield||0 %|
Latest discussion posts More
“" FTSE FOR THE WEEK (FTSE:UKX)A Friday was irritating. It's one thing to speculate "all the action will happen at the open", quite another to glance at the FTSE at 8:01am ...”▼
“Good RNS today to push sp up around 13% to #1.90. The FDA and EMA have agreed with Summit the parameters for the Phase 3 trials. Essentially the authorities want the Phase 3 ...”▼
“Great to see sp recovering from the 140s pre new year. Expect to see C dif deal before end of H1. Progress on DMD scientific or anecdotal could come at any time by end of H1. ...”▼
Codes & Symbols
|Symbols||SUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM|